drugset / Trial / NCT07522242

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

NCT07522242 ↗

Phase 2 Recruiting 200 enrolled Laboratoires Thea
RandomizedParallel-groupDouble-blindPrevention

Summary

Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.

Timeline

Start
2026-01-21
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject T10430 Unknown — Topical

Indications